Ensysce Biosciences (ENSC) Long-Term Investments (2017 - 2021)

Ensysce Biosciences (ENSC) has reported Long-Term Investments for 5 consecutive years, with $12.7 million the latest figure, recorded in Q1 2021.

• In Q1 2021, Long-Term Investments fell 79.31% year-over-year to $12.7 million; the TTM figure through Mar 2021 stood at $12.7 million (down 79.31% YoY), while the FY2020 annual figure was $12.6 million, down 93.53% from the prior year.
• Long-Term Investments held at $12.7 million in Q1 2021 per ENSC's latest filing, from $12.6 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $205.8 million in Q3 2019 and bottomed at $53492.0 in Q3 2020.
• Historically, Long-Term Investments has averaged $136.9 million across 5 years, with a median of $200.4 million in 2017.
• Annual changes were most pronounced in 2019 — Long-Term Investments grew 1.82% — and 2020, when it plunged 99.97%.
• Ensysce Biosciences' Long-Term Investments stood at $200.1 million in 2017, then gained by 1.4% to $202.9 million in 2018, then slipped by 3.75% to $195.3 million in 2019, then plunged by 93.53% to $12.6 million in 2020, then advanced by 0.5% to $12.7 million in 2021.
• Business Quant data shows ENSC's Long-Term Investments at $12.7 million in Q1 2021, $12.6 million in Q4 2020, and $53492.0 in Q3 2020.